Prime Medicine, Inc. (PRME) total debt
Prime Medicine, Inc. (PRME) carried total debt of $116.43M at the end of fiscal 2025 (December 31, 2025). That is 185.4% higher than the $40.79M of fiscal 2024. Figures as of 18 Nov 2026, 01:53 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- $116.43M
- Change on fiscal 2024
- +185.4%
- Highest on record
- $116.43Mfiscal 2025
- Lowest on record
- $13.63Mfiscal 2023
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Prime Medicine, Inc. total debt, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $116.43M in fiscal 2025 and the lowest $13.63M in fiscal 2023.
Total debt was 1.0× shareholders' equity at the end of fiscal 2025.
Total debt by fiscal year
Prime Medicine, Inc. total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | $116.43M | 185.4% up | 1.0× | |
| 2024 | $40.79M | 199.2% up | 0.3× | |
| 2023 | $13.63M | 52.6% down | 0.1× | |
| 2022 | $28.75M | — | 0.1× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Prime Medicine, Inc., figure by figure
- Prime Medicine, Inc. market cap
- Prime Medicine, Inc. revenue
- Prime Medicine, Inc. earnings
- Prime Medicine, Inc. earnings per share (EPS)
- Prime Medicine, Inc. P/E ratio
- Prime Medicine, Inc. P/S ratio
- Prime Medicine, Inc. P/B ratio
- Prime Medicine, Inc. free cash flow
- Prime Medicine, Inc. operating margin
- Prime Medicine, Inc. dividend
- Prime Medicine, Inc. shares outstanding
- Prime Medicine, Inc. cash on hand
- Prime Medicine, Inc. total assets
- Prime Medicine, Inc. return on equity (ROE)
- Prime Medicine, Inc. return on invested capital (ROIC)
Prime Medicine, Inc. (PRME) overview: price, valuation and scorecard
Prime Medicine, Inc. total debt: questions and answers
How much debt does Prime Medicine, Inc. have?
Prime Medicine, Inc. (PRME) carried total debt of $116.43M at the end of fiscal 2025 (December 31, 2025). That is 185.4% higher than the $40.79M of fiscal 2024.
What are the highest and lowest total debt figures on record for Prime Medicine, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $116.43M in fiscal 2025 and the lowest $13.63M in fiscal 2023.
How does Prime Medicine, Inc.'s debt compare with its equity?
Total debt was 1.0× shareholders' equity at the end of fiscal 2025.
How is Prime Medicine, Inc.'s total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Prime Medicine, Inc. (PRME) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/PRME/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.